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BACKGROUND
Reproductive-age women need effective interventions to prevent the acquisition of 
human immunodeficiency virus type 1 (HIV-1) infection.
METHODS
We conducted a randomized, placebo-controlled trial to assess daily treatment with 
oral tenofovir disoproxil fumarate (TDF), oral tenofovir–emtricitabine (TDF-FTC), or 
1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in 
women in South Africa, Uganda, and Zimbabwe. HIV-1 testing was performed month-
ly, and plasma TFV levels were assessed quarterly.
RESULTS
Of 12,320 women who were screened, 5029 were enrolled in the study. The rate of 
retention in the study was 91% during 5509 person-years of follow-up. A total of 312 
HIV-1 infections occurred; the incidence of HIV-1 infection was 5.7 per 100 person-
years. In the modified intention-to-treat analysis, the effectiveness was −49.0% with 
TDF (hazard ratio for infection, 1.49; 95% confidence interval [CI], 0.97 to 2.29), 
−4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5% with TFV 
gel (hazard ratio, 0.85; 95% CI, 0.61 to 1.21). In a random sample, TFV was detected 
in 30%, 29%, and 25% of available plasma samples from participants randomly 
assigned to receive TDF, TDF-FTC, and TFV gel, respectively. Independent predictors 
of TFV detection included being married, being older than 25 years of age, and being 
multiparous. Detection of TFV in plasma was negatively associated with character-
istics predictive of HIV-1 acquisition. Elevations of serum creatinine levels were seen 
more frequently among participants randomly assigned to receive oral TDF-FTC 
than among those assigned to receive oral placebo (1.3% vs. 0.2%, P = 0.004). We 
observed no significant differences in the frequencies of other adverse events.
CONCLUSIONS
None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in 
an intention-to-treat analysis. Adherence to study drugs was low. (Funded by the 
National Institutes of Health; VOICE ClinicalTrials.gov number, NCT00705679.)
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Daily oral preexposure prophylaxis with 300 mg of tenofovir disoproxil fu-marate (TDF), alone or in combination 
with 200 mg of emtricitabine (FTC) (TDF-FTC 
[Truvada, Gilead Sciences]), reduces the risk of 
acquisition of human immunodeficiency virus 
type 1 (HIV-1) by 50% or more among persons 
with high adherence to the regimen, with dem-
onstrated efficacy in men who have sex with 
men, heterosexuals, and injection-drug users.1-4 
On the basis of these observations, in July 2012 
the Food and Drug Administration approved daily 
treatment with Truvada for the prevention of HIV-1 
acquisition, and the Centers for Disease Control 
and Prevention has issued guidelines for its use.5 
However, Truvada was found to be ineffective in 
preventing HIV-1 acquisition among women in 
the Preexposure Prophylaxis Trial for HIV Preven-
tion among African Women (FEM-PrEP), whose 
rate of adherence, as assessed on the basis of 
plasma tenofovir (TFV) levels, was less than 40%.6
The topical application of antiretroviral agents, 
including TFV, is effective in preventing rectal 
and cervicovaginal infection with simian immu-
nodeficiency virus in macaques.7,8 Participants in 
the Centre for the AIDS Programme of Research 
in South Africa (CAPRISA) 004 trial who were 
assigned to receive pericoital treatment with 1% 
TFV gel had a 39% reduction in the risk of HIV-1 
acquisition relative to women assigned to receive 
placebo, and greater protection was observed with 
higher adherence.9
The potential for protection with oral or topi-
cal antiretroviral agents, which we anticipated 
would have distinct safety, acceptability, and phar-
macokinetic profiles, informed the design of the 
Vaginal and Oral Interventions to Control the Epi-
demic (VOICE) trial (MTN-003), which was initiated 
while the trials described above were under way. 
The aim of the VOICE trial was to estimate the ef-
fectiveness of daily treatment with vaginal TFV gel, 
as compared with placebo gel, and of oral TDF and 
oral TDF-FTC, as compared with oral placebo, in 
preventing sexually acquired HIV-1 infection in 




From September 2009 through June 2011, we 
screened 12,320 women at 15 sites in South Africa, 
Uganda, and Zimbabwe (Table S1 in the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org). We enrolled women 18 to 
45 years of age who were neither pregnant nor 
breast-feeding and who reported recent vaginal 
intercourse, were using effective contraception, 
and had normal renal, hematologic, and he-
patic function (Table S2 in the Supplementary 
Appendix).
Randomization and Study Procedures
Participants were randomly assigned in a 1:1:1:1:1 
ratio to one of five regimens: oral TDF (300 mg) 
and TDF-FTC placebo, oral TDF-FTC (300 mg of 
TDF and 200 mg of FTC) and TDF placebo, oral 
TDF placebo and oral TDF-FTC placebo, vaginal 
1% TFV gel, or vaginal placebo gel.10 Participants 
were counseled to use the products daily. All par-
ticipants were tested for sexually transmitted in-
fections at the time of enrollment, annually, and 
when indicated. Standard HIV risk-reduction coun-
seling, individualized adherence counseling, con-
doms, and hepatitis B immunization were pro-
vided. The study product was withheld if the 
woman became pregnant, began breast-feeding, 
and had clinical or laboratory adverse events. Site-
based community educators and advisory boards 
provided input into the study design and con-
duct. All procedures are described in Table S3 in 
the Supplementary Appendix and in the study 
protocol (available at NEJM.org).
Study End Points
The primary effectiveness end point was HIV-1 
infection, identified by seroconversion as deter-
mined with the use of a standard algorithm (Fig. 
S2 in the Supplementary Appendix). HIV-1 test-
ing was performed monthly, and the study prod-
uct was immediately withheld if any rapid HIV 
assay was positive, pending confirmation by means 
of an enzyme-linked immunosorbent assay and 
subsequent Western blotting. Participants who 
became infected with HIV-1 were offered enroll-
ment in a seroconversion study and were re-
ferred for care. All end points were reviewed by 
an HIV-1 end-point adjudication committee, the 
members of which were unaware of the study-
group assignments. Participants were followed 
for 8 weeks after the last visit at which empty 
containers and unused study product were re-
turned, so that any delayed HIV-1 seroconversions 
could be detected.
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Safety monitoring included monthly interviews 
and pregnancy testing, quarterly serum chemical 
testing and urine dipstick analysis of protein and 
glucose levels, and twice-yearly pelvic examina-
tions. Adherence to the study product was assessed 
by means of a questionnaire administered by in-
terview monthly; by monthly in-clinic counts of 
returned pills, empty pill bottles, or unused vagi-
nal applicators; and by a quarterly audio computer-
assisted self-interview (ACASI). Condom use and 
sexual practices were also assessed with an ACASI.
Study Oversight
The study was funded by the National Institutes 
of Health. Study products were donated by Gil-
ead Sciences (TDF, TDF-FTC, and oral placebo) 
and CONRAD (TFV and placebo gels); neither 
CONRAD nor Gilead played any additional role 
in the study or had access to the data presented 
here. Written informed consent was obtained from 
all participants. The study was designed and con-
ducted by members of the protocol team, who 
collected data, monitored conduct, and performed 
statistical analyses. The study was approved an-
nually by the institutional review boards and 
ethics committees at all participating institutions 
(Table S4 in the Supplementary Appendix). Prog-
ress was reviewed every 3 to 6 months by an in-
dependent data and safety monitoring board. The 
investigators, participating institutions, and spon-
sor agreed to maintain the confidentiality of data. 
All the authors had access to the data and assume 
responsibility for the integrity and completeness 
of the results and the fidelity to the protocol. The 
manuscript was prepared by a designated writ-
ing team of investigators, all of whom are listed 
authors, who collectively agreed to submit it for 
publication.
Drug Level and Viral Resistance Analyses
Plasma TFV concentrations were determined with 
the use of a validated ultra-performance liquid 
chromatographic–tandem mass spectrometric 
(UPLC-MS/MS) method11; the limit of TFV and 
FTC quantification was 0.31 ng per milliliter. TFV 
and FTC were extracted from cervicovaginal fluid 
collected on Dacron swabs by means of solid-
phase extraction, and analyte concentrations were 
determined with UPLC-MS/MS. The lower limits 
of quantification were 0.625 ng per swab for TFV 
and 2.5 ng per swab for FTC. Plasma HIV-1 geno-
typing (codons 1 through 99 of protease and co-
dons 1 through 350 of reverse transcriptase) was 
performed, with the use of the ViroSeq HIV-1 
Genotyping System, version 2.0 (Celera), in pa-
tients who underwent seroconversion and who 
had plasma HIV-1 RNA levels of 200 copies per 
milliliter or higher. All sequences were edited 
manually, and nucleotide positions with multiple 
peaks that were more than 20% above background 
were considered to be mixtures. Resistance muta-
tions were identified with the use of the Stanford 
Calibrated Population Resistance Tool.12
Statistical Analysis
The study was designed to enroll 1000 women per 
group who would be followed through the end of 
the study or for a maximum of 36 months, with 
a minimum follow-up period of 12 months. In 
the study design, we assumed a background HIV 
incidence rate of 3% and aimed to analyze 94 HIV 
seroconversions for each of three pairwise com-
parisons. The study was designed to have 90% 
power to detect at least 55% effectiveness while 
ruling out effectiveness of less than 25%, with 
false positive error rate of 0.0025.
The primary analysis was performed in a 
modified intention-to-treat population and in-
cluded as end points only HIV-1 infections that 
were deemed to have been acquired after enroll-
ment; participants with detectable HIV-1 RNA in 
plasma at enrollment were categorized as having 
acute HIV-1 infection and were excluded. Cox pro-
portional-hazards models stratified according to 
site were used to assess the time to HIV-1 sero-
conversion. The cumulative probabilities of in-
fection were estimated by means of the Kaplan–
Meier method. Analyses were conducted with the 
use of SAS software, version 9.2 (SAS Institute), 
and R software, version 2.15.1 (R Project for Sta-
tistical Computing). All P values are two-sided.
For the analysis of plasma TFV concentrations, 
we used a case–cohort design,13 in which a ran-
dom subcohort was selected from the active study-
product groups (cohort) and was enriched with 
all remaining participants who had undergone 
HIV-1 seroconversion (cases). For every participant 
who underwent seroconversion, we sampled ap-
proximately three participants who remained un-
infected with HIV-1 throughout participation. Pre-
dictors of TFV detection were assessed with the 
use of generalized estimating equations with a 
logistic link function and exchangeable working 
correlation matrix. We conducted multivariate sur-
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vival analyses to assess the association between 
the detection of the drug in plasma obtained at 
follow-up visits and time to HIV-1 infection.14 
Generalized-estimating-equation models with a 
binomial link, exchangeable correlation structure, 
and robust standard errors were used to determine 
baseline predictors of plasma TFV detection. A 
Cox regression was used to determine baseline 
predictors of HIV acquisition and to analyze the 




We assessed 12,320 women for eligibility and 
randomly assigned 5029 women to a study group 
(Fig. 1). The primary exclusion criterion was HIV-1 
infection (32%; range, 3 to 53% according to site). 
A total of 61.8% of the participants were from 
Durban, South Africa; the majority of participants 
from this site were unmarried women who were 
younger, on average, than other participants. The 
characteristics of the participants were similar 
among the study groups (Table 1). The mean age 
was 25.3 years, 21% of the women were married, 
and 71% used injectable hormonal contraception. 
The participants reported a mean number of 2.5 
episodes of vaginal intercourse during the 7 days 
before enrollment.
Follow-up and Adherence Assessments
The primary end point was determined for 4969 
participants (99% of enrollees) during 5509 per-
son-years of follow-up, which represented 95% of 
the anticipated person-years. The rate of retention 
in the study, defined as completion of end-of-study 
visit procedures (including physical examination 
and relevant laboratory testing), was 91% and did 
not differ significantly among study groups. In 
September 2011, the data and safety monitoring 
board recommended that treatment with oral TDF 
alone be discontinued for futility; in November 
2011, a similar determination was made regard-
ing TFV gel. The board recommended that the 
TDF-FTC and oral placebo groups continue fol-
low-up until the end of the study, in August 2012.
On the basis of returned-product counts, the 
mean rate of adherence (calculated as the propor-
tion of product not returned divided by the num-
ber of days since the previous visit at which study 
products were dispensed) was 86% (Table 2). On 
the basis of self-reporting, the mean rate of ad-
herence was 90% as reported in interviews and 
88% as assessed with an ACASI. In the ACASIs, 
47% of the participants rated their ability to use 
the product daily, as instructed, during the pre-
vious 4 weeks as “very good or excellent.”15 The 
study product was withheld for 246 person-years, 
primarily because of pregnancy; the rates for with-
holding of the study product were similar among 
the study groups.
Effect of TDF, TDF-FTC, and TFV on HIV-1 
Acquisition
There were 334 seroconversions among study par-
ticipants, including 22 events that were defined as 
acute HIV-1 infection with RNA present at enroll-
ment. When these 22 participants were excluded, 
the incidence of HIV infection was 5.7 per 100 
person-years (0.8 to 9.9 per 100 person-years ac-
cording to site). The incidence was highest among 
participants who were younger than 25 years of 
age (8.0 per 100 person-years) and among those 
who were unmarried (7.2 per 100 person-years).
Of the 312 seroconversions included in the 
primary analysis, 52 occurred in the TDF group, 
61 in the TDF-FTC group, 61 in the TFV gel group, 
60 in the oral placebo group, and 70 in the pla-
cebo gel group (Table 3). The effectiveness was 
−49.0% with TDF (hazard ratio for infection, 
1.49; 95% confidence interval [CI], 0.97 to 2.29), 
−4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 
0.73 to 1.49), and 14.5% with TFV gel (hazard ratio, 
0.85; 95% CI, 0.61 to 1.21). There was no signifi-
cant difference in the rate of HIV-1 seroconversion 
between a group receiving any study product and 
the group receiving the corresponding placebo, 
and the incidence of HIV-1 seroconversion did not 
change significantly during the study (Fig. 2). 
HIV-1 seroconversion was identified in 34 women 
after the scheduled completion of the period of 
product use; the rates did not differ according to 
study group.
Antiretroviral Resistance
Of 334 participants who underwent HIV-1 sero-
conversion, 322 (96%) had plasma available with 
sufficient HIV-1 RNA copies for resistance testing. 
Among the 21 of these participants who were 
infected at the time of randomization, resistance 
to FTC (M184I/V mutation) was detected in 2 par-
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ticipants who had been assigned to the TDF-FTC 
group (Table S5 in the Supplementary Appendix). 
Among the 301 participants who acquired HIV-1 
infection after randomization, resistance to FTC 
(M184V mutation) developed in 1 participant in 
the TDF-FTC group. No participants who acquired 
HIV-1 infection were infected with TDF-resistant 
strains (K65R mutation). Strains with the M184I/V 
or K65R mutation were not present in 33 partici-
pants who were infected after they stopped using 
the study product.
Detection of Study Drug in Biologic Samples 
and Association with HIV-1 Seroconversion
The case–cohort sample comprised 647 partici-
pants from the active-product study groups, from 
whom 2987 plasma samples were available for TFV 
measurement. In the random subcohort, TFV was 
detected in a mean of 30% of available plasma 
samples collected quarterly from participants ran-
domly assigned to the TDF group, in 29% of avail-
able plasma samples from the TDF-FTC group, 
and in 25% from the TFV gel group (Table 2). At 
Figure 1. Study Cohort.
The most common reason for exclusion from participation was prevalent HIV infection (33% of excluded participants). Failure to com-
plete screening and enrollment within the 56-day window resulted in the exclusion of 21% of potential participants. Collectively, abnor-
mal laboratory results accounted for 16% (range, 5 to 23) of all exclusions; the most common results were positivity for the hepatitis B 
surface antigen (3.4%), anemia (2.9%), abnormal (grade 2 or higher) Papanicolaou smear (2.7%), and a urine-dipstick result of 2+ or 
higher for protein (2.5%). Conditions related to reproductive outcomes resulted in the exclusion of 9% of the women: 5.9% were preg-
nant at the time of screening, with the remainder reporting current breast-feeding or the intention to become pregnant in the next 2 
years. A total of 22 participants who were found to have HIV-1 RNA, as assessed by means of a polymerase-chain-reaction assay, at the 
time of enrollment were classified as having acute HIV-1 infection and were excluded from the analysis. FTC denotes emtricitabine, TDF 
tenofovir disoproxil fumarate, and TFV tenofovir.
5029 Underwent randomization
12,320 Patients were assessed for eligibility
7291 Were excluded
2308 Were HIV-positive
4983 Were not HIV-positive
1007 Were assigned to
receive oral TDF
65 Were lost to follow-up
32 Declined to participate
13 Relocated
15 Could not be contacted
5 Had other reasons
993 Were included in the
analysis




9 Were lost to follow-up
1003 Were assigned to
receive oral TDF-FTC
139 Were lost to follow-up
63 Declined to participate
30 Relocated
25 Could not be contacted
21 Had other reasons
985 Were included in the
analysis




9 Were lost to follow-up
1009 Were assigned to
receive oral placebo
117 Were lost to follow-up
62 Declined to participate
23 Relocated
17 Could not be contacted
3 Died
12 Had other reasons
999 Were included in the
analysis




9 Were lost to follow-up
1007 Were assigned to
receive vaginal 1% TFV gel
79 Were lost to follow-up
36 Declined to participate
19 Relocated
9 Could not be contacted
2 Died
13 Had other reasons
996 Were included in the
analysis
11 Were excluded from the
analysis
4 Were HIV-positive 
at enrollment
7 Were lost to follow-up
1003 Were assigned to
receive vaginal placebo gel
69 Were lost to follow-up
29 Declined to participate
20 Relocated
12 Could not be contacted
1 Died
7 Had other reasons
996 Were included in the
analysis
7 Were excluded from the
analysis
3 Were HIV-positive 
at enrollment
4 Were lost to follow-up
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the first quarterly visit, less than 40% of plasma 
samples in all three active-product groups had 
detectable TFV. A total of 58% of the participants 
in the TDF group, 50% in the TDF-FTC group, and 
57% in the TFV gel group had no plasma TFV de-
tected at any quarterly visit (Table S6 in the Supple-
mentary Appendix). Among participants randomly 
assigned to the TFV gel group, TFV was detected 
in a mean of 49% of swabs tested (Table 2).
Baseline characteristics associated with plasma 
TFV detection in the active-product groups, ad-
justed for study site, included being older than 
25 years of age (adjusted odds ratio, 1.62; 95% CI, 
1.12 to 2.34), being married (adjusted odds ratio, 
2.24; 95% CI, 1.12 to 4.49), having an independent 
income (adjusted odds ratio, 1.42; 95% CI, 0.98 to 
2.07), and being multiparous (adjusted odds ratio, 















Mean 25.3±5.2 25.5±5.1 25.2±5.2 25.3±5.2 25.3±5.2 25.3±5.1
Median (range) 24 (18–40) 25 (18–40) 24 (18–40) 24 (18–40) 24 (18–40) 24 (18–40)
Some secondary school education 
or higher — no. (%)
4622 (92) 924 (92) 929 (93) 926 (92) 920 (91) 923 (92)
Earns own income — no. (%) 2881 (57) 569 (57) 569 (57) 586 (58) 587 (58) 570 (57)
Live births — no. 1.5±1.1 1.6±1.1 1.5±1.1 1.5±1.2 1.5±1.1 1.5±1.2
Currently married — no. (%) 1052 (21) 207 (21) 209 (21) 211 (21) 210 (21) 215 (21)
≥2 male sex partners in the past  
3 months — no./total no. (%)
1104/4991 (22) 236/1001 (24) 208/994 (21) 244/1003 (24) 217/998 (22) 199/995 (20)
Episodes of vaginal intercourse in 
the past 7 days — no.†
2.5±3.1 2.5±2.8 2.5±3.4 2.5±2.6 2.6±3.6 2.6±2.9
Condom use during last vaginal sex 
— no./total no. (%)
3766/4420 (85) 763/880 (87) 760/888 (86) 742/872 (85) 768/895 (86) 733/885 (83)
Anal sex in the previous 3 mo — 
no./total no. (%)
868/4991 (17) 164/1001 (16) 175/994 (18) 174/1003 (17) 179/998 (18) 176/995 (18)
Contraception method — no. (%)
Injectable 3565 (71) 709 (70) 723 (72) 700 (69) 707 (70) 726 (72)
Oral pills 1140 (23) 226 (22) 223 (22) 238 (24) 238 (24) 215 (21)
Infection present
Chlamydia trachomatis — no. (%)‡ 611 (12) 122 (12) 117 (12) 127 (13) 116 (12) 129 (13)
Neisseria gonorrhoeae — no. (%)‡ 163 (3) 42 (4) 27 (3) 34 (3) 24 (2) 36 (4)
Trichomonas vaginalis — no. (%)§ 301 (6) 68 (7) 54 (5) 66 (7) 62 (6) 51 (5)
Syphilis — no. (%)¶ 68 (1) 12 (1) 15 (1) 16 (2) 14 (1) 11 (1)
HSV-2 — no./total no. (%)‖ 2289/5005 (46) 482/1002 (48) 449/997 (45) 455/1006 (45) 438/1004 (44) 465/996 (47)
Bacterial vaginosis — no./ 
total no. (%)**
2023/5010 (40) 422/1000 (42) 410/1002 (41) 401/1008 (40) 397/1003 (40) 393/997 (39)
*  Plus–minus values are means ±SD. FTC denotes emtricitabine, HSV-2 herpes simplex virus type 2, TDF tenofovir disoproxil fumarate, and 
TFV tenofovir.
†  Data on the number of sex acts in the past 7 days were available for 4566 participants.
‡  Testing for C. trachomatis and N. gonorrhoeae was performed with the use of a strand-displacement amplification assay (BD ProbeTec, 
Becton Dickinson).
§  Testing for T. vaginalis was performed with the use of the OSOM Trichomonas Rapid Test (Genzyme).
¶  Syphilis testing was performed with the use of a rapid plasma reagin screening test followed by a confirmatory microhemagglutinin assay 
for Treponema pallidum or a T. pallidum hemagglutination assay for reactive samples.
‖  HSV-2 seropositivity was determined with the use of the HerpeSelect 2 enzyme immunoassay (Focus Technologies) at the time of enroll-
ment; an index value of 3.5 or greater was considered to be a positive result.
**  Bacterial vaginosis was determined by the Nugent score on Gram’s staining of vaginal fluid.
Table 1. Baseline Characteristics of the Study Participants, According to Study Group.*
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were also associated with a lower risk of HIV-1 
acquisition in both placebo groups, which suggests 
that participants with better adherence had a lower 
risk of acquiring HIV than did participants who 
were less likely to adhere (Table S6E in the Supple-
mentary Appendix). We adjusted for these char-
acteristics when assessing the association between 
TFV detection and HIV-1 acquisition. A Cox regres-
sion assessing the time to HIV-1 infection and the 
detection of TFV in plasma at each follow-up visit 
did not yield a significant association. However, 
plasma TFV detection at the first quarterly visit 
was predictive of TFV detection at later visits. 
Most women in whom TFV was not detected at 
the first quarterly visit had none detected at sub-
sequent visits (70% in the FTC-TDF group, 83% 
in the TDF group, and 72% in the TFV gel group). 
When participants were evaluated according to 
whether TFV was detected in plasma at the first 
quarterly visit, those in the TFV gel group with 
detectable TFV levels had a significantly lower 
likelihood of HIV acquisition than did those with 
no TFV detected (HIV incidence per 100 person-
years: 1.9 vs. 6.1, adjusted hazard ratio, 0.34; 
95% CI, 0.13 to 0.87; P = 0.02). Similar results 
were obtained when participants were grouped 
according to whether the drug was ever detected 
or was never detected at any time during the 
follow-up period (Table S6C in the Supplementary 
Appendix).
Safety and Adverse-Event Profiles
Elevated serum creatinine levels were seen more 
frequently among participants randomly assigned 
to the oral TDF-FTC group than among those in 
the oral placebo group (1.3% vs. 0.2%, P = 0.004); 
all but one of these elevations were mild (Table 
S7G in the Supplementary Appendix). We observed 
no other significant differences between the groups 



















Mean rate of adherence (%)
Assessed by clinic-based product count† 86 84 88 90 83 84
Assessed by face-to-face interview‡ 90 91 90 91 90 90
Assessed by ACASI§ 88 87 87 88 88 89
Mean proportion of quarterly plasma samples 
with TFV detected (%)¶
NA 30 29 NA 25 NA
Proportion of women with TFV not detected in 
any quarterly plasma samples (%)¶
NA 58 50 NA 57 NA
Mean proportion of vaginal swab samples 
with TFV detected (%)‖
NA NA NA NA 49 NA
Proportion of women with TFV not detected in 
any vaginal swab samples (%)‖
NA NA NA NA 41 NA
*  ACASI denotes audio computer-assisted self-interview, and NA not applicable.
†  Participants were asked to return empty pill bottles, unused pills, and unused vaginal gel applicators at each monthly 
visit. Percentages are the estimated mean proportions of doses not returned and presumed to have been used. The 
mean proportion in the Total column is based on 4994 participants with follow-up data.
‡  In the interviews, women were asked to report the number of doses of study product they used in the previous week, 
and these were summed across monthly follow-up visits. The mean proportion in the Total column is based on 4935 
participants.
§  In the ACASI, women were asked to report the number of doses of study product they used in the previous week, and 
these were summed across quarterly follow-up visits. The mean proportion in the Total column is based on 4739 par-
ticipants.
¶  Proportions were calculated among the 488 participants in the random cohort of the case–cohort subset who had quar-
terly plasma samples available (158 in the TDF group, 157 in the TDF-FTC group, and 173 in the TFV gel group); the 
median number of quarterly samples tested per participant was 3 (range, 1 to 10).
‖  Proportions were calculated among the 170 participants randomly assigned to the TFV gel group who were in the ran-
dom cohort of the case–cohort subset and provided at least one vaginal swab sample (with samples collected at 
6-month intervals). A total of 255 swabs were collected from these participants between the month 5 and month 17 vis-
its and were available for analysis; 85 participants had two swabs tested, and 85 had one swab tested.
Table 2. Adherence to Study Products.*
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incidence of pregnancy was 7.8 per 100 person-
years and did not differ by group.
Discussion
In our population of predominantly young, un-
married women in sub-Saharan Africa, daily ad-
herence to study products — oral or vaginal 
TFV-based formulations — was low, and no regi-
men significantly reduced the risk of HIV-1 ac-
quisition in a modified intention-to-treat analysis. 
Lower adherence, as assessed by measurement of 
TFV levels in plasma, was associated with charac-
teristics that predicted a higher risk of HIV ac-
quisition. The detection of TFV in plasma among 
participants randomly assigned to the TFV gel 
group was associated with a lower likelihood of 
HIV acquisition after adjustment for these char-
acteristics. However, we were not able to measure 
(and thus control for) the most important poten-
tial confounder in this analysis — namely, the 
likelihood of HIV-1 exposure. On the basis of 
differences in characteristics between participants 
who used the study products and those who did 
not use the study products, the likelihood of 
HIV-1 exposure may also have differed between 
these two groups, beyond our ability to control 
for it. Moreover, as observed in other trials of pre-
exposure prophylaxis, participants with detectable 
drug levels did acquire HIV-1 infection.
Our results are consistent with those of the 
FEM-PrEP trial, in which daily TDF-FTC use did 
not reduce HIV-1 acquisition among women and 
in which study-drug adherence was also low.6 
These findings have implications for biomedical 
prevention research in these populations, as well 
as for the implementation of interventions with 
proven efficacy. First, despite increasing coverage 
with antiretroviral therapy for the treatment of 
HIV-infected persons and the potential for as-
sociated declines in community-wide incidence,16 
we observed HIV-1 incidence rates exceeding those 
we anticipated, particularly among young women 
in Durban — up to 9.9 per 100 person-years.
Second, most participants did not use the 
study products daily, a finding that is not consis-
tent with prestudy assessments of the willingness 
of the target populations to use such products,17 
adherence assessments based on clinic-based prod-
uct counts and self-reporting, and the high rates 
of retention. Despite using multiple measures to 
assess adherence, including ACASIs, we found 
that fewer than half the participants disclosed 
nonadherence or barriers to use, and in fact prod-
ucts were returned in a manner consistent with 
high adherence. This highlights the need for mea-
sures of adherence that do not rely solely on self-
reporting and that are not easily manipulated by 
participants, such as real-time biologic monitor-
ing of drug levels. In a qualitative ancillary study 
conducted concurrently among randomly selected 
participants in the VOICE trial in Johannesburg, 
consistent themes emerged: the unknown effi-
cacy of products, their identification with HIV 
infection, and the lack of social support for study 
participation.11 These may be some of the factors 
that discouraged consistent use of the study 
products.
Third, our findings contrast with those from 
other trials. In the Partners PrEP trial, the reduc-
tions in the risk of HIV-1 acquisition among 
HIV-1–uninfected women were 71% with TDF and 
66% with TDF-FTC.2 Adherence was good; this 
was probably facilitated by the enrollment of se-
rodiscordant couples, the disclosure of HIV 
infection status within couples, and the partners’ 
Result Oral TDF* Oral TDF-FTC Oral Placebo TFV Gel Placebo Gel
Active Agent Placebo
Person-years 823 838 1284 1308 1024 1030
Number of HIV-1 infections 52 35 61 60 61 70
HIV-1 incidence — cases per 
100 person-years (95% CI)
6.3 (4.7–8.3) 4.2 (2.9–5.8) 4.7 (3.6–6.1) 4.6 (3.5–5.9) 6.0 (4.6–7.6) 6.8 (5.3–8.6)
Hazard ratio (95% CI) 1.49 (0.97–2.29) — 1.04 (0.73–1.49) — 0.85 (0.61–1.21) —
P value 0.07 — 0.81 — 0.37 —
*  Data were censored on the date when sites were asked to discontinue treatment in the oral TDF group.
Table 3. Primary Efficacy Results.
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mutual engagement in product use.18 The VOICE 
participants who were most likely to adhere were 
similar, in terms of age and marital status, to 
women in the Partners PrEP trial. In the CAPRISA 
004 trial, pericoital administration of 1% TFV gel 
was associated with a reduction in the risk of 
HIV-1 acquisition of 39% (95% CI, 6 to 60).9 Ef-
fectiveness was associated with adherence, as 
assessed through self-reporting, applicator counts, 
and TFV concentration in the cervicovaginal flu-
id.19 Pericoital administration of 1% TFV gel is 
currently being studied in the Follow-on African 
Consortium for Tenofovir Studies (FACTS) 001 
Trial in South Africa.
We observed one case of resistance (M184V 
mutation) in a participant in an active-product 
group who underwent seroconversion 11 months 
after enrollment. Five cases of resistance have been 
reported in participants in active-product groups 
in trials of preexposure prophylaxis; all five par-
ticipants were enrolled while they had acute HIV-1 
infection.1-3 In the FEM-PrEP trial, three cases of 
M184I/V resistance occurred within 12 weeks af-
ter enrollment in the TDF-FTC group; the inves-
tigators could not exclude the possibility that the 
participants were infected at the time of enroll-
ment.6 Acquired resistance was rare in the VOICE 
trial, a finding that could be explained by consis-
tently low, rather than intermittent, adherence 
to the study product.
Our results reaffirm the need for effective and 
acceptable prevention interventions for women at 
high risk for sexual acquisition of HIV-1 and sug-
gest that more accurate measures are critical for 
the estimation of product use during biomedical 
HIV-1–prevention trials.7 Real-time monitoring of 
biomarkers of product adherence may facilitate 
the efficiency of such trials. Products that do not 
require daily use, including sustained delivery of 
antiretroviral agents from vaginal rings or injec-
tions, may be more suitable for some women. Suc-
cessful adoption of daily preexposure prophylaxis 
may require different social and operational strate-
gies to support daily use. Indeed, our retention 
and qualitative findings suggest that participants 
valued the study and its contribution to their 
health.11 It is critical that investigators understand 
the participants’ motivation for enrolling in a 
study, as well as their perceptions of the investi-
gational products, and that they leverage this in-
sight when conducting biomedical research on 
HIV-1 prevention.
Figure 2. Cumulative Probability of HIV-1 Infection, According to Study Group.
The numbers shown below the graph are the numbers of participants who were at risk at the start of each quarterly 
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